BIIB vs STRO · P/E 21, rev $9.89B vs rev $62.0M
Biogen Inc (BIIB) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. STRO currently screens at market cap $470.8M.
Not investment advice. Open the BIIB and STRO stock pages for the full models.
Not investment advice.